Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genomic Analysis Reveals That Immune Function Genes Are Strongly Linked to Clinical Outcome in the North Central Cancer Treatment Group N9831 Adjuvant Trastuzumab Trial

21 Jan 2015

Abstract excerpt

PURPOSE: To develop a genomic signature that predicts benefit from trastuzumab in human epidermal growth factor receptor 2-positive breast cancer. PATIENTS AND METHODS: DASL technology was used to quantify mRNA in samples from 1,282 patients enrolled onto the Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer (North Central Cancer Treatment Group N9831 [NCCTG-N9831])...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Cancer Treatment Studies
Share to Cancer Immunotherapy and Biomarkers
Share to HER2/EGFR in Cancer Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 25605861
DOI: 10.1200/jco.2014.57.6298

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genomic Analysis Reveals That Immune Function Genes Are Strongly Linked to Clinical Outcome in the North Central Cancer Treatment Group N9831 Adjuvant Trastuzumab TrialPMID 25605861Read ↗

Peripheral blood gene expression signatures of systemic immunity predict tumor microenvironment biology and therapeutic response in breast cancerSemantic proximity Read ↗

Immune Effective Score As A Predictor Of Response To Neoadjuvant Trastuzumab Therapy And A Prognostic Indicator For HER2-positive Breast CancerSemantic proximity Read ↗

Immunogenic Subtypes of Breast Cancer Delineated by Gene Classifiers of Immune Responsiveness.Semantic proximity Read ↗

Genomic and transcriptomic profiles associated with response to eribulin and nivolumab combination in HER-2-negative metastatic breast cancer.Semantic proximity Read ↗

Gene Modules and Response to Neoadjuvant Chemotherapy in Breast Cancer Subtypes: A Pooled AnalysisSemantic proximity Read ↗

Molecular Pathways: Involvement of Immune Pathways in the Therapeutic Response and Outcome in Breast CancerSemantic proximity Read ↗

An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancerSemantic proximity Read ↗

Microtubule targeting agents influence the clinical benefit of immune response in early breast cancerSemantic proximity Read ↗

Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo.Semantic proximity Read ↗

A Transcriptomic Immunologic Signature Predicts Favorable Outcome in Neoadjuvant Chemotherapy Treated Triple Negative Breast TumorsSemantic proximity Read ↗

Immune Gene Signature as a Predictor of CDK4/6 Inhibitor Response in HR+/HER2– Breast CancerSemantic proximity Read ↗

Immune gene expression and response to chemotherapy in advanced breast cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.